Immuron Limited (IMC.AX)
AUD 0.06
(0.0%)
AUD 0.06
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 | -6.93 Million AUD | -83.2% |
| 2023 | -3.78 Million AUD | -32.66% |
| 2022 | -2.85 Million AUD | 65.96% |
| 2021 | -8.38 Million AUD | -186.43% |
| 2020 | -2.92 Million AUD | 37.14% |
| 2019 | -4.65 Million AUD | -54.65% |
| 2018 | -3.01 Million AUD | 55.75% |
| 2017 | -6.8 Million AUD | 3.74% |
| 2016 | -7.06 Million AUD | -162.6% |
| 2015 | -2.69 Million AUD | -7.89% |
| 2014 | -2.49 Million AUD | 29.5% |
| 2013 | -3.53 Million AUD | -54.04% |
| 2012 | -2.29 Million AUD | 11.47% |
| 2011 | -2.59 Million AUD | -36.17% |
| 2010 | -1.9 Million AUD | 17.78% |
| 2009 | -2.31 Million AUD | 18.91% |
| 2008 | -2.85 Million AUD | 12.89% |
| 2007 | -3.28 Million AUD | 7.83% |
| 2006 | -3.55 Million AUD | -166.98% |
| 2005 | -1.33 Million AUD | -14.75% |
| 2004 | -1.16 Million AUD | 0.0% |
| 2003 | - AUD | 100.0% |
| 2002 | -1.69 Million AUD | -9.37% |
| 2001 | -1.55 Million AUD | 0.0% |
| 2000 | - AUD | 0.0% |
| 1999 | - AUD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 FY | -6.93 Million AUD | -83.2% |
| 2024 Q2 | -2.07 Million AUD | 0.0% |
| 2024 Q4 | -4.86 Million AUD | 0.0% |
| 2023 FY | -3.78 Million AUD | -32.66% |
| 2023 Q2 | -1.97 Million AUD | 0.0% |
| 2023 Q4 | -1.8 Million AUD | 0.0% |
| 2022 Q4 | -1.04 Million AUD | 0.0% |
| 2022 Q2 | -1.81 Million AUD | 0.0% |
| 2022 FY | -2.85 Million AUD | 65.96% |
| 2021 Q2 | -5.73 Million AUD | 0.0% |
| 2021 FY | -8.38 Million AUD | -186.43% |
| 2021 Q4 | -2.64 Million AUD | 0.0% |
| 2020 Q2 | -1.49 Million AUD | 0.0% |
| 2020 FY | -2.92 Million AUD | 37.14% |
| 2020 Q4 | -1.43 Million AUD | 0.0% |
| 2019 FY | -4.65 Million AUD | -54.65% |
| 2019 Q4 | -3.05 Million AUD | 0.0% |
| 2019 Q2 | -1.58 Million AUD | 0.0% |
| 2018 Q4 | -1.11 Million AUD | 0.0% |
| 2018 Q2 | -1.89 Million AUD | 0.0% |
| 2018 FY | -3.01 Million AUD | 55.75% |
| 2017 Q4 | -3.39 Million AUD | 0.0% |
| 2017 FY | -6.8 Million AUD | 3.74% |
| 2017 Q2 | -3.4 Million AUD | 0.0% |
| 2016 Q4 | -2.53 Million AUD | 0.0% |
| 2016 Q2 | -3.06 Million AUD | 0.0% |
| 2016 FY | -7.06 Million AUD | -162.6% |
| 2015 Q4 | -1.38 Million AUD | 0.0% |
| 2015 Q2 | -1.3 Million AUD | 0.0% |
| 2015 FY | -2.69 Million AUD | -7.89% |
| 2014 Q2 | -1.43 Million AUD | 0.0% |
| 2014 FY | -2.49 Million AUD | 29.5% |
| 2014 Q4 | -1.11 Million AUD | 0.0% |
| 2013 Q3 | -884.77 Thousand AUD | 40.18% |
| 2013 FY | -3.53 Million AUD | -54.04% |
| 2013 Q1 | -574.38 Thousand AUD | 0.0% |
| 2013 Q4 | -2.06 Million AUD | -132.83% |
| 2013 Q2 | -1.47 Million AUD | -157.51% |
| 2012 Q1 | -648.79 Thousand AUD | 0.0% |
| 2012 FY | -2.29 Million AUD | 11.47% |
| 2012 Q4 | -574.38 Thousand AUD | 0.0% |
| 2012 Q3 | -574.38 Thousand AUD | 0.0% |
| 2012 Q2 | -574.38 Thousand AUD | 11.47% |
| 2011 Q3 | -648.79 Thousand AUD | 0.0% |
| 2011 Q4 | -648.79 Thousand AUD | 0.0% |
| 2011 FY | -2.59 Million AUD | -36.17% |
| 2011 Q2 | -648.79 Thousand AUD | -36.17% |
| 2011 Q1 | -476.45 Thousand AUD | 0.0% |
| 2010 Q3 | -476.45 Thousand AUD | 0.0% |
| 2010 FY | -1.9 Million AUD | 17.78% |
| 2010 Q4 | -476.45 Thousand AUD | 0.0% |
| 2010 Q2 | -476.45 Thousand AUD | 17.78% |
| 2010 Q1 | -579.45 Thousand AUD | 0.0% |
| 2009 FY | -2.31 Million AUD | 18.91% |
| 2009 Q1 | -714.58 Thousand AUD | 0.0% |
| 2009 Q2 | -579.45 Thousand AUD | 18.91% |
| 2009 Q3 | -579.45 Thousand AUD | 0.0% |
| 2009 Q4 | -579.45 Thousand AUD | 0.0% |
| 2008 Q1 | -820.3 Thousand AUD | 0.0% |
| 2008 Q2 | -714.58 Thousand AUD | 12.89% |
| 2008 FY | -2.85 Million AUD | 12.89% |
| 2008 Q4 | -714.58 Thousand AUD | 0.0% |
| 2008 Q3 | -714.58 Thousand AUD | 0.0% |
| 2007 Q1 | -889.98 Thousand AUD | 0.0% |
| 2007 FY | -3.28 Million AUD | 7.83% |
| 2007 Q2 | -820.3 Thousand AUD | 7.83% |
| 2007 Q4 | -820.3 Thousand AUD | 0.0% |
| 2007 Q3 | -820.3 Thousand AUD | 0.0% |
| 2006 Q2 | -889.98 Thousand AUD | -166.98% |
| 2006 Q1 | -333.34 Thousand AUD | 0.0% |
| 2006 Q4 | -889.98 Thousand AUD | 0.0% |
| 2006 Q3 | -889.98 Thousand AUD | 0.0% |
| 2006 FY | -3.55 Million AUD | -166.98% |
| 2005 Q2 | -333.34 Thousand AUD | -14.75% |
| 2005 FY | -1.33 Million AUD | -14.75% |
| 2005 Q4 | -333.34 Thousand AUD | 0.0% |
| 2005 Q3 | -333.34 Thousand AUD | 0.0% |
| 2005 Q1 | -290.5 Thousand AUD | 0.0% |
| 2004 FY | -1.16 Million AUD | 0.0% |
| 2004 Q2 | -290.5 Thousand AUD | 0.0% |
| 2004 Q3 | -290.5 Thousand AUD | 0.0% |
| 2004 Q4 | -290.5 Thousand AUD | 0.0% |
| 2004 Q1 | - AUD | 0.0% |
| 2003 Q1 | -424.77 Thousand AUD | 0.0% |
| 2003 Q2 | - AUD | 100.0% |
| 2003 Q3 | - AUD | 0.0% |
| 2003 Q4 | - AUD | 0.0% |
| 2003 FY | - AUD | 100.0% |
| 2002 Q1 | -388.37 Thousand AUD | 0.0% |
| 2002 Q4 | -424.77 Thousand AUD | 0.0% |
| 2002 Q3 | -424.77 Thousand AUD | 0.0% |
| 2002 Q2 | -424.77 Thousand AUD | -9.37% |
| 2002 FY | -1.69 Million AUD | -9.37% |
| 2001 Q3 | -388.37 Thousand AUD | 0.0% |
| 2001 Q4 | -388.37 Thousand AUD | 0.0% |
| 2001 Q2 | -388.37 Thousand AUD | 0.0% |
| 2001 Q1 | - AUD | 0.0% |
| 2001 FY | -1.55 Million AUD | 0.0% |
| 2000 Q1 | - AUD | 0.0% |
| 2000 FY | - AUD | 0.0% |
| 2000 Q4 | - AUD | 0.0% |
| 2000 Q3 | - AUD | 0.0% |
| 2000 Q2 | - AUD | 0.0% |
| 1999 Q2 | - AUD | 0.0% |
| 1999 Q3 | - AUD | 0.0% |
| 1999 Q4 | - AUD | 0.0% |
| 1999 FY | - AUD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| AdAlta Limited | -5.38 Million AUD | -28.909% |
| Acrux Limited | -5.8 Million AUD | -19.603% |
| Actinogen Medical Limited | -13.04 Million AUD | 46.82% |
| AnteoTech Limited | -8.88 Million AUD | 21.886% |
| Argenica Therapeutics Limited | -5.47 Million AUD | -26.599% |
| Arovella Therapeutics Limited | -8.74 Million AUD | 20.685% |
| Anatara Lifesciences Ltd | -1.45 Million AUD | -378.001% |
| Alterity Therapeutics Limited | -19.12 Million AUD | 63.725% |
| Amplia Therapeutics Limited | -4.5 Million AUD | -54.036% |
| Avecho Biotechnology Limited | -3.43 Million AUD | -101.858% |
| Bio-Gene Technology Limited | -2.4 Million AUD | -187.939% |
| Biome Australia Limited | -1.67 Million AUD | -315.336% |
| Biotron Limited | -3.43 Million AUD | -101.86% |
| Botanix Pharmaceuticals Limited | -13.86 Million AUD | 49.985% |
| BTC Health Limited | 1.05 Million AUD | 757.353% |
| Chimeric Therapeutics Limited | -12.52 Million AUD | 44.637% |
| CSL Limited | 2.64 Billion AUD | 100.263% |
| Clarity Pharmaceuticals Ltd | -42.32 Million AUD | 83.61% |
| Clinuvel Pharmaceuticals Limited | 35.63 Million AUD | 119.466% |
| Cynata Therapeutics Limited | -9.74 Million AUD | 28.813% |
| Dimerix Limited | -17.07 Million AUD | 59.374% |
| EZZ Life Science Holdings Limited | 6.96 Million AUD | 199.605% |
| Hexima Limited | -933.87 Thousand AUD | -642.816% |
| Island Pharmaceuticals Limited | -2.86 Million AUD | -142.185% |
| Immutep Limited | -39.89 Million AUD | 82.613% |
| Imugene Limited | -149.68 Million AUD | 95.365% |
| Invex Therapeutics Ltd | -1.64 Million AUD | -322.519% |
| Memphasys Limited | -4.44 Million AUD | -56.167% |
| Nanollose Limited | -1.15 Million AUD | -499.796% |
| Neuren Pharmaceuticals Limited | 157.08 Million AUD | 104.416% |
| Noxopharm Limited | -3.57 Million AUD | -93.872% |
| NeuroScientific Biopharmaceuticals Limited | 324.21 Thousand AUD | 2239.649% |
| Nyrada Inc. | -1.38 Million AUD | -400.42% |
| Orthocell Limited | -7.18 Million AUD | 3.398% |
| PharmAust Limited | -9.03 Million AUD | 23.199% |
| Patrys Limited | -3.53 Million AUD | -96.006% |
| Paradigm Biopharmaceuticals Limited | -58.65 Million AUD | 88.173% |
| Proteomics International Laboratories Limited | -6.37 Million AUD | -8.794% |
| Prescient Therapeutics Limited | -8.23 Million AUD | 15.794% |
| PYC Therapeutics Limited | -37.72 Million AUD | 81.612% |
| Race Oncology Limited | -13.81 Million AUD | 49.803% |
| Radiopharm Theranostics Limited | -47.94 Million AUD | 85.533% |
| Recce Pharmaceuticals Ltd | -17.66 Million AUD | 60.723% |
| Starpharma Holdings Limited | -8.16 Million AUD | 15.04% |
| Telix Pharmaceuticals Limited | 5.21 Million AUD | 233.121% |
| Tissue Repair Ltd | -4.13 Million AUD | -67.636% |
| Zelira Therapeutics Limited | -36.56 Million AUD | 81.03% |